Trial Profile
Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ORIENT
- Sponsors AbbVie
- 17 Feb 2016 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
- 17 Feb 2016 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
- 17 Feb 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.